Medications for Tourette Syndrome and Tics: Options, Benefits, and Risks
Author: Angela Bogdanova · Published: October 12, 2026 · Editorial Policy
Research cluster: Tic Disorders, Tourette Syndrome & Repetitive Behaviors · Written by Artificial Sapiens
Tics are involuntary, recurrent movements or sounds that may be distressing, painful, exhausting, or disruptive. Medication can reduce their severity for some people with Tourette syndrome or another persistent tic disorder, but choosing a drug requires a comparison of expected improvement, adverse effects, co-occurring conditions, and the person's own priorities. The objective is improved functioning and well-being, rather than complete elimination of every tic. CDC treatment guidance
The medication options with the most established clinical use include the dopamine-modulating antipsychotics aripiprazole and risperidone and the alpha-2 adrenergic agonists clonidine and guanfacine. Other treatments—including topiramate, focal botulinum toxin injections, and selected older antipsychotics—may be reasonable in particular circumstances. As of October 2026, ecopipam has promising phase 2b and phase 3 evidence but remains investigational in the United States. The American Academy of Neurology guideline and European clinical guideline frame these as individualized decisions.
When do tics need medication?
A tic is a clinical symptom, while Tourette syndrome, persistent motor or vocal tic disorder, and provisional tic disorder are diagnostic categories defined by the types of tics, age at onset, duration, and clinical assessment. Tourette syndrome involves both motor and vocal tics at some point during the illness, with an onset before age 18 and a history longer than one year. The two types need not occur simultaneously. Medication decisions follow an assessment of symptoms and their impact; a description of blinking, throat clearing, or other repetitive behavior alone cannot establish a tic disorder. CDC diagnostic criteria
Treatment is generally considered when tics cause injury or pain; impair writing, speaking, reading, sleep, or everyday tasks; provoke substantial distress; or interfere with school, work, relationships, or participation. A person's preferences matter: a conspicuous tic that does not trouble the person may require no medication, while a less visible neck tic that causes pain may justify intervention. Clinicians should discuss the person's goals directly, rather than assuming that reducing all visible movements is necessarily the priority. CDC treatment guidance AAN guideline
Watchful waiting is an active, evidence-based option when tics are not functionally impairing. It can include education, reduction of stigma, access to school or workplace accommodations, and reassessment as circumstances change. Tics frequently fluctuate over days and months, and many children experience meaningful improvement during adolescence; clinicians should therefore avoid attributing every natural rise or fall in tic frequency to a drug. AAN guideline
Medication, CBIT, or both?
Comprehensive Behavioral Intervention for Tics (CBIT) is a structured treatment that includes awareness training, competing-response practice, and changes to circumstances that influence tics. When available and appropriate, it is generally preferred as an initial active treatment because it has demonstrated benefit without medication-related adverse effects. CBIT can be used with medication; a person does not have to fail behavioral treatment before a clinician considers medicine when symptoms are severe, painful, or otherwise urgent. CDC: CBIT AAN guideline
Medication and behavioral treatment address different aspects of tic management. A drug may lower the intensity or frequency of tics, while CBIT helps a person respond to premonitory urges and adapt to tic-provoking situations. Neither approach means that tics are voluntary, caused by poor motivation, or reliably controllable through willpower. Access to trained CBIT clinicians, the person's developmental level, preferences, and the burden of co-occurring conditions all influence the care plan. CDC treatment guidance
Overview of medication classes
The following comparison describes the broad pattern of evidence, rather than a ranking that applies to every patient. Most drug studies are short, differ in age and baseline severity, and measure tic scores more consistently than quality of life or long-term functioning. The 2019 AAN recommendations and 2022 European guidelines remain central guidance documents; newer trials can change how individual investigational treatments are viewed. AAN guideline European guideline
Alpha-2 adrenergic agonists: clonidine and guanfacine
Clonidine and guanfacine act on central alpha-2 adrenergic receptors and can help regulate attention and impulse-related signaling. In tic disorders, their average anti-tic effects tend to be modest, but they can be particularly useful when a child has both tics and ADHD. Some clinicians consider them before antipsychotics for mild-to-moderate impairing tics, especially when attention symptoms also warrant treatment. Guanfacine and clonidine have differing formulations and pharmacokinetic properties, and dose schedules must be tailored by a prescriber. AAN guideline European guideline
The principal adverse effects are drowsiness, fatigue, dizziness, low blood pressure, and a slowed heart rate. Sedation may lessen as a person adapts, but it can also interfere with school performance or driving. Blood pressure and pulse should be measured before and during treatment. The AAN additionally recommends QTc monitoring for guanfacine extended release in people with particular cardiac histories, family histories of long-QT syndrome, or concomitant QT-prolonging medicines. These medicines should be tapered under medical supervision because abrupt discontinuation can produce rebound hypertension. AAN recommendations 8a–8f
The evidence is not uniformly positive. A small randomized trial of extended-release guanfacine did not show a statistically significant tic benefit, and meta-analyses suggest that the apparent effect is stronger in groups with co-occurring ADHD. A family selecting guanfacine for isolated severe tics should understand that the expected benefit may be limited. European guideline, guanfacine evidence
Dopamine-modulating antipsychotics: aripiprazole, risperidone, and others
Dopamine transmission in cortico-striatal circuits is relevant to tic generation and modulation. Several antipsychotic medications, despite their name, are prescribed to reduce tics in people who do not have a psychotic disorder. Their actions differ: aripiprazole has partial dopamine D2 receptor agonist properties, whereas risperidone primarily blocks D2 and serotonin 5-HT2 receptors. Drugs in this group generally have more substantial anti-tic evidence than alpha-2 agonists, accompanied by more intensive adverse-effect monitoring. European guideline AAN guideline
Aripiprazole
Aripiprazole is a common choice for moderately severe or severe impairing tics when medication is indicated. Randomized pediatric trials establish efficacy, and the European guideline favors it among dopamine-modulating agents because of its relative tolerability profile. In the United States, oral aripiprazole products have an FDA-labeled indication for Tourette's disorder in pediatric patients ages 6–18; prescribing to other ages or in different formulations requires attention to the exact product label and clinical circumstances. European guideline US prescribing information
Somnolence, fatigue, nausea, restlessness or akathisia, and increased appetite or weight are relevant concerns. Aripiprazole is sometimes described as metabolically gentler than certain alternatives, but weight and metabolic changes still occur, and an individual may find akathisia especially distressing. Antipsychotic-related involuntary movements, including tardive dyskinesia, remain important to monitor even when average risks differ between agents. The FDA label also contains broader class and age-specific safety warnings that prescribers review with patients and families. AAN guideline US prescribing information
Risperidone
Risperidone has long-standing randomized-trial and systematic-review support for tic reduction. It may be selected when clinical characteristics, previous treatment response, or availability favor it. Major tradeoffs include increased appetite and weight, altered glucose or lipid parameters, sedation, elevated prolactin, and extrapyramidal symptoms such as stiffness or restlessness. Prolactin-related effects can include breast changes, menstrual disturbances, or sexual side effects, depending on age and clinical context. Because the balance differs from that of aripiprazole, comparison should be specific to the person. European guideline AAN guideline
Haloperidol, pimozide, tiapride, and other antipsychotics
Haloperidol and pimozide are older dopamine-receptor-blocking treatments with historical and regulatory roles in tic management. They can reduce tics but may cause more troublesome movement-related or cardiac adverse effects, so they are generally reserved for selected situations after considering better-tolerated options. Pimozide carries important QT-prolongation and drug-interaction concerns. Tiapride is used in some European settings and has supportive evidence, but it is not routinely available in the United States. Ziprasidone and other agents have narrower tic-specific evidence and their own monitoring requirements. AAN guideline European guideline
A drug being FDA-approved for a particular Tourette indication does not automatically make it a better first choice than an off-label treatment. Conversely, an off-label medication can be a medically reasonable option when supported by evidence and an individualized benefit–risk assessment. US approval varies by drug, formulation, age, and indication; clinicians should verify the current product label rather than relying on broad claims that every medication in a class is approved for tics. CDC treatment guidance US aripiprazole label
Other pharmacological options for selected situations
Topiramate
Topiramate, an antiseizure medication with multiple neural signaling actions, has evidence of possible tic benefit from a comparatively small trial and is an alternative considered in the AAN guideline. Its most consequential potential adverse effects include difficulties with concentration, word finding, memory, or cognitive speed; drowsiness; paresthesias; decreased appetite or weight loss; and kidney stones. Pregnancy-related risks and drug interactions, including potential effects on some hormonal contraceptives, require individualized counseling where relevant. Topiramate is not interchangeable with first-choice therapies merely because one study showed a favorable average tic score. AAN guideline Randomized topiramate trial
Botulinum toxin injections for focal tics
For an adolescent or adult with a particularly troublesome localized motor tic—or a selected vocal tic involving identifiable muscles—botulinum toxin injections may be considered by an experienced specialist. Evidence supports a benefit in some focal tics and possibly their premonitory urges, but the treatment does not address a generalized pattern of many tics. Temporary muscle weakness and, after injections affecting the larynx, voice weakness or reduced volume are meaningful risks. Repeat injections may be necessary as the effect wears off. AAN guideline
Cannabinoid-based treatment
Small studies of tetrahydrocannabinol-containing treatments in adults have suggested possible anti-tic effects, but the evidence base is limited and cannot establish safety or effectiveness for children. Cognitive, psychiatric, dependence-related, and driving risks complicate decisions, while legal and product-quality conditions vary by jurisdiction. The AAN urges clinicians to counsel patients about evidence and risks, and pregnancy and adolescence warrant particular caution. Cannabinoids should not be portrayed as an established first-line treatment for Tourette syndrome. AAN guideline European guideline
VMAT2 inhibitors: why appealing biology has not consistently translated into benefit
Vesicular monoamine transporter 2 (VMAT2) inhibitors such as deutetrabenazine and valbenazine reduce presynaptic monoamine packaging and are used for certain other movement disorders. Interest in their use for tics arose from their mechanism and small preliminary studies. Yet two larger randomized pediatric Tourette trials of deutetrabenazine failed to show a statistically meaningful tic reduction over placebo, and controlled trials of valbenazine also produced disappointing results. Their efficacy in tardive dyskinesia or Huntington-related chorea cannot be assumed to apply to Tourette tics. ARTISTS 1 trial ARTISTS 2 trial
A 2025 systematic review compared newer trial data on aripiprazole and valbenazine, illustrating continuing investigation. Different study designs, populations, and outcomes help explain why pooled or exploratory findings should be interpreted alongside the negative primary results of pivotal randomized trials. VMAT2 inhibitors should not be introduced to families as proven or FDA-approved Tourette treatments on the strength of evidence from other indications. 2025 systematic review ARTISTS 2 trial
Ecopipam: promising 2026 data, investigational US status
Ecopipam is a selective dopamine D1 receptor antagonist, a distinct mechanism from the widely used D2-modulating antipsychotics. A 2023 randomized phase 2b trial in children and adolescents found a greater average reduction in tic scores than placebo over 12 weeks. In a 2026 phase 3 randomized-withdrawal trial, pediatric participants who initially improved on ecopipam had a lower risk of relapse when they continued medication than when assigned to placebo (hazard ratio 0.47; 95% CI 0.26–0.84). These are meaningful findings but answer different questions: the phase 2b study evaluated short-term improvement; the selected-responder phase 3 design primarily tested maintenance of response. Pediatrics phase 2b study JAMA Neurology phase 3 study
In the 2026 trial, commonly reported adverse events included sleepiness, anxiety, headache, insomnia, and fatigue. No clinically meaningful weight or metabolic signal emerged during the study, although longer-term real-world experience is still developing. Only 14 adults entered the randomized phase, so the adult result was statistically inconclusive; pediatric findings cannot simply be generalized to all adults. As of October 12, 2026, FDA orphan-drug records identify ecopipam as designated but not approved for its Tourette indication. It remains investigational rather than an available FDA-approved Tourette prescription. 2026 phase 3 study FDA orphan-drug status
How effective are medications in real life?
Tic medication trials often use the Yale Global Tic Severity Scale (YGTSS), a clinician-rated measure of tic characteristics and associated impairment. A decrease in its Total Tic Score can indicate a treatment effect, but the number alone does not tell whether an individual feels better at school, experiences less pain, or can participate more freely. Interpretation depends on baseline severity, the magnitude of improvement, time frame, safety, and the person's most important goals. A YGTSS score measures severity; it is not a standalone test that diagnoses Tourette syndrome. AAN guideline Ecopipam trial methods
Medication effects are averages across diverse trial participants. One person may have a substantial decrease in a painful shoulder tic with manageable drowsiness; another may see little improvement but substantial weight gain or restlessness. Placebo response, natural fluctuation, short follow-up, differences in age and co-occurring disorders, and the scarcity of long-term head-to-head trials limit claims that any single drug is universally most effective. The best clinical decision also weighs the burden of taking and monitoring a medication. European guideline AAN guideline
Side effects and medical monitoring
Every treatment plan should specify which adverse effects are relevant to the selected drug, what to measure at baseline, the follow-up schedule, and what symptoms require urgent contact. Monitoring is an integral part of treatment, not an optional extra added only if problems develop. In general, medication is started at a low dose, adjusted gradually when appropriate, and periodically reviewed for a continuing indication. European guideline AAN guideline
Antipsychotics: movement, metabolic, hormonal, and cardiac safety
Movement symptoms to monitor include acute dystonia, parkinsonian stiffness or tremor, akathisia (an intensely uncomfortable need to move), and persistent abnormal movements that could represent tardive dyskinesia. Akathisia may be misread as increased tics or behavioral agitation, so new movements after treatment initiation or dose changes need careful clinical assessment. Some adverse effects can persist, making early identification important. Clinicians also track weight or BMI, metabolic parameters, and—depending on the drug and symptoms—prolactin-related effects. AAN recommendations 9a–9f
An electrocardiogram and QTc assessment are particularly important with pimozide or ziprasidone and when drugs that prolong the QT interval are combined, as specified in AAN guidance. Drug–drug interactions and underlying cardiac conditions may change what monitoring is needed. Clinicians should review every prescription, over-the-counter medicine, and supplement, including treatments for ADHD, anxiety, or other conditions. AAN guideline
Alpha-2 agonists: sedation, low blood pressure, and withdrawal
With clonidine or guanfacine, dizziness on standing, fainting, unusual fatigue, or a very slow pulse warrant a discussion with the prescriber. Monitoring pulse and blood pressure is particularly important during dose changes and when other medications affect cardiovascular function. Abrupt discontinuation can cause rebound increases in blood pressure, so patients and caregivers need a practical plan for missed doses, prescription refills, and supervised tapering. AAN recommendations 8c–8f
What symptoms require prompt medical attention?
Severe muscle stiffness with fever or marked confusion, fainting or concerning heart-rhythm symptoms, a new severe involuntary movement, an allergic reaction, or sudden major changes in mental state require urgent clinical assessment. A prescriber should also be contacted promptly about substantial restlessness, worsening mood, new suicidal thoughts, or adverse effects that interfere with daily functioning. Emergency symptoms require local emergency services. These are safety signals for medical evaluation, not grounds for diagnosing a drug reaction from a webpage. US aripiprazole prescribing information AAN guideline
ADHD, OCD, autism, anxiety, and other co-occurring conditions
Tourette syndrome often co-occurs with ADHD, OCD, anxiety disorders, or other neurodevelopmental conditions. Treatment should identify which symptoms are most impairing instead of using tic severity as a proxy for the person's entire clinical burden. Medication that reduces motor or vocal tics may leave attention problems, obsessions, compulsions, distress, or sleep difficulties unchanged. Conversely, improving another condition may help functioning even if tic counts change little. CDC overview European guideline
Tourette syndrome with ADHD
Clonidine and guanfacine can address both tics and some ADHD symptoms, but some children require a more effective ADHD-specific treatment. Stimulant medication, especially methylphenidate at therapeutic doses, does not consistently worsen tics in controlled studies and should not automatically be withheld because Tourette syndrome is present. A 2024 network meta-analysis found stimulants effective for ADHD symptoms without a group-level increase in tic severity, while alpha-2 agonists benefited both domains. Individual trajectories still deserve monitoring because tics fluctuate and some people experience temporary changes. 2025 systematic review and network meta-analysis AAN guideline
Tics and OCD or compulsions
An action performed in response to a sensory premonitory urge may resemble a compulsive ritual, and a person can have both tics and clinically significant OCD. Their mechanisms and treatment goals need separate assessment. OCD commonly warrants exposure and response prevention and, when indicated, OCD-specific medication; tic medication should not be presented as a substitute. See the English Hub discussion of OCD and tic disorders and the differential explanation of OCD versus Tourette syndrome. European guideline
Autism and other repetitive movements
Autistic stereotypies or self-stimulatory movements and tic phenomena can coexist, but they should not be equated. Nor do sudden-onset functional tic-like behaviors necessarily follow the same course or respond to the same interventions as childhood-onset neurodevelopmental tics. When the movement history is atypical, medication selection follows specialist assessment rather than applying a Tourette medication algorithm to every repetitive behavior. European guideline CDC diagnostic criteria
Selecting a medicine: a shared decision rather than a universal first choice
A clinician and patient can begin by specifying a concrete treatment target, such as reducing painful head jerks, making meals or class participation easier, or limiting disruptive vocal tics. They then review diagnosis and differential diagnoses; past treatments; ADHD, OCD, and other conditions; personal and family cardiac or metabolic history; current medicines; potential pregnancy-related issues where relevant; and access to behavioral care. The preferred medicine often depends on this complete profile. AAN guideline European guideline
For mild-to-moderate impairing tics with ADHD, an alpha-2 agonist may offer a practical combined approach, provided fatigue and cardiovascular risks are acceptable. For more severe impairing tics, aripiprazole or another antipsychotic with evidence may have a stronger anticipated tic benefit but also demands active movement and metabolic monitoring. Topiramate, botulinum toxin injections, or selected other agents may be considered when standard choices are ineffective, contraindicated, or poorly tolerated. These examples illustrate decision factors; they are not prescriptions for a particular individual. European guideline AAN guideline
A realistic trial should include an agreed interval for assessing benefit, documentation of adverse effects, and a plan for adjustments. If response is insufficient, clinicians may revisit the diagnosis and treatment goal, adherence, concurrent stressors, CBIT access, medication tolerability, and co-occurring disorders before changing or combining agents. Polypharmacy increases interaction and monitoring burdens, and combining medications does not automatically improve tic control. AAN guideline
Starting, changing, and stopping medication
Tic medicines are typically titrated under supervision rather than started at a high dose. Families should know the exact formulation and administration schedule, what to do if a dose is missed, which symptoms to record, and when the next review occurs. The recommended dose varies by age, body weight, indication, metabolic interactions, kidney or liver function, and formulation; patient education should therefore avoid treating a general web dosage table as a personal instruction. US aripiprazole prescribing information European guideline
As tics change naturally over time, periodic reassessment is essential. If a person has sustained improvement or feels the adverse effects outweigh benefit, a planned dose reduction may be appropriate. Alpha-2 agonists should be tapered to reduce rebound hypertension; antipsychotics should generally be tapered over weeks to months to minimize withdrawal-related abnormal movements. The schedule is individualized and supervised, particularly when several medicines or co-occurring conditions are involved. AAN guideline
Children, teenagers, and adults
In children, goals should be defined with the child and family, taking school, fatigue, learning, physical safety, and social participation into account. Adolescents should be included in decisions about effects on alertness, weight, body image, autonomy, and adherence. Many people have changing tic severity across puberty and adolescence, making periodic treatment reassessment valuable. Pediatric safety and efficacy data cannot be assumed to transfer unchanged to adults, or vice versa. AAN guideline CDC treatment guidance
In adults with established childhood-onset Tourette syndrome, treatment may target painful or socially disruptive residual tics, while other clinical needs may have become more prominent. A new tic-like symptom beginning in adulthood requires a careful history and differential diagnosis, including possible medication-related movements, functional tic-like symptoms, or other neurological conditions. The fact that an antipsychotic may reduce Tourette tics does not establish that it is appropriate for every new movement. European guideline CDC diagnostic criteria
What clinical research still needs to answer
Important gaps include sustained real-world functional outcomes; comparative effectiveness between commonly used medicines; effects in adults, young children, and underrepresented populations; treatment sequencing and combination strategies; and long-term safety during changing neurodevelopmental stages. Study populations often exclude clinically complex patients and rely on short-term symptom scales. These limitations are reasons to use individualized monitoring, not reasons to dismiss the benefits shown in controlled trials. AAN guideline European guideline
The ecopipam program demonstrates why drug development needs careful stage-by-stage interpretation. Its 2023 phase 2b study supports short-term symptom reduction; the 2026 randomized-withdrawal trial supports maintenance of response among pediatric participants who initially improved, while adult efficacy remains uncertain. Regulatory approval and post-approval safety experience are separate questions. Likewise, the negative randomized deutetrabenazine trials show that a plausible dopamine-related mechanism does not guarantee tic benefit. Ecopipam phase 2b Ecopipam phase 3 Deutetrabenazine ARTISTS trials
Frequently asked questions
What is the best medication for Tourette syndrome?
There is no universal best drug. Aripiprazole and risperidone have substantial evidence for reducing impairing tics, while clonidine and guanfacine may be appealing when tics coexist with ADHD. Choice depends on age, severity, treatment goals, medical history, side-effect risk, and preferences. AAN guideline European guideline
Can medication completely stop tics?
Some people experience major improvement, but complete and durable tic elimination should not be promised. Treatment aims to reduce clinically meaningful burden, and tics can continue to wax and wane during medication use. CDC treatment guidance
Does everyone with Tourette syndrome need medication?
No. If tics cause little or no impairment, education and watchful waiting may be sufficient. CBIT is an evidence-supported active option when treatment is wanted or needed. AAN guideline CDC CBIT guidance
Are medications prescribed for Tourette syndrome antipsychotics?
Some are, including aripiprazole and risperidone. Their use for tics does not imply that the person has psychosis. Other options include clonidine, guanfacine, topiramate, and focal botulinum toxin injections. European guideline
Will ADHD stimulants make Tourette tics worse?
Randomized research does not support a general rule that properly prescribed stimulants worsen tics. Clinicians monitor each patient's course and distinguish medication-related change from the natural waxing and waning of tics. Effective ADHD treatment may be crucial for functioning. 2024 network meta-analysis
Can children take aripiprazole for Tourette syndrome?
Certain oral aripiprazole products have a US FDA indication for Tourette's disorder in ages 6–18. Suitability and dosing require a qualified prescriber's assessment and follow-up for weight, movement, and other adverse effects. Approval is formulation- and indication-specific. US prescribing information
Are guanfacine and clonidine safe to stop suddenly?
No abrupt discontinuation should be attempted without a prescriber-directed plan. These medicines can cause rebound hypertension when stopped suddenly and should be tapered. AAN guideline
Is ecopipam FDA-approved for Tourette syndrome in 2026?
As of October 12, 2026, ecopipam is investigational for Tourette syndrome in the United States. Positive pediatric trial data do not themselves constitute regulatory approval. FDA orphan-drug database 2026 randomized trial
Can a tic severity score tell me which drug to take?
No. Severity scales help track change, but they do not replace diagnosis, assessment of co-occurring conditions, review of contraindications, or shared treatment decisions. A score by itself does not determine whether medication is necessary. AAN guideline
What if the medicine works but its side effects are difficult?
Tell the prescriber which effects are affecting daily life. Reviewing the dose, timing, medicine choice, and alternative treatments may be appropriate. A medication that produces a favorable tic score but unacceptable sedation, weight gain, or restlessness may have an unfavorable overall benefit–risk balance. Never change or stop a prescribed regimen without a safety plan. CDC treatment guidance AAN guideline
Related Articles
References
American Academy of Neurology (AAN). (2019). Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology, 92, 896–906. https://doi.org/10.1212/WNL.0000000000007466
Centers for Disease Control and Prevention (CDC). (2026). Behavioral Treatment for Tics That Works. https://www.cdc.gov/tourette-syndrome/articles/behavioral-treatment-for-tics-that-works.html
Centers for Disease Control and Prevention (CDC). (2026). Diagnosing Tic Disorders. https://www.cdc.gov/tourette-syndrome/diagnosis/index.html
Centers for Disease Control and Prevention (CDC). (2026). Treatment of Tourette Syndrome. https://www.cdc.gov/tourette-syndrome/treatment/index.html
Coffey, B., et al. (2021). Efficacy and safety of fixed-dose deutetrabenazine in children and adolescents for tics associated with Tourette syndrome. JAMA Network Open, 4, e2129397. https://doi.org/10.1001/jamanetworkopen.2021.29397
Farhat, L. C., et al. (2024). Pharmacological interventions for attention-deficit/hyperactivity disorder in children and adolescents with Tourette disorder: A systematic review and network meta-analysis. Journal of Child and Adolescent Psychopharmacology, 34, 373–382. https://doi.org/10.1089/cap.2024.0049
Gilbert, D. L., et al. (2023). Ecopipam for Tourette syndrome: A randomized trial. Pediatrics, 151, e2022059574. https://doi.org/10.1542/peds.2022-059574
Gilbert, D. L., et al. (2026). Efficacy and safety of ecopipam for Tourette syndrome: A phase 3 randomized clinical trial. JAMA Neurology, 83, 645–653. https://doi.org/10.1001/jamaneurol.2026.1431
Jankovic, J., et al. (2021). Safety and efficacy of flexible-dose deutetrabenazine in children and adolescents with Tourette syndrome. JAMA Network Open, 4, e2128204. https://doi.org/10.1001/jamanetworkopen.2021.28204
Jankovic, J., Jimenez-Shahed, J., & Brown, L. W. (2010). A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. Journal of Neurology, Neurosurgery & Psychiatry, 81, 70–73. https://doi.org/10.1136/jnnp.2009.185348
Muneer, M. A., et al. (2026; published online 2025). Efficacy of aripiprazole and valbenazine in the treatment of Tourette syndrome: A systematic review and meta-analysis of randomized controlled trials. Acta Neurologica Belgica, 126, 747–756. https://doi.org/10.1007/s13760-025-02864-2
National Library of Medicine. (2026). DailyMed: Aripiprazole tablets, prescribing information, Tourette's disorder indication and precautions. DailyMed product label
Roessner, V., et al. (2022). European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: Pharmacological treatment. European Child & Adolescent Psychiatry, 31, 425–441. https://doi.org/10.1007/s00787-021-01899-z
U.S. Food and Drug Administration. (2026). Orphan Drug Designations and Approvals: Ecopipam hydrochloride for pediatric Tourette syndrome. FDA database entry